Compare Abeona Therapeutics Inc (ABEO) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $7.5 (market cap $421.19M), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.16. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | LQD | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | — |
52-Week High | $7.45 | $112.91 |
52-Week Low | $4.17 | $105.96 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
LQD trades at $106.215, up 0.24% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings while facing pressure from rising Treasury yields and inflation concerns. Recent dividend distributions provide income support, but technical indicators suggest caution with 17 sell signals versus 2 buy signals.
The outlook remains challenged by bond market volatility and Fed policy uncertainty. Investment opportunities exist for income-focused investors through dividends, but risks include interest rate sensitivity and macroeconomic pressures from oil price fluctuations and geopolitical tensions affecting fixed income markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
